FUSCO, ALFREDO
 Distribuzione geografica
Continente #
AS - Asia 4.605
NA - Nord America 2.551
EU - Europa 952
SA - Sud America 905
AF - Africa 76
OC - Oceania 8
Continente sconosciuto - Info sul continente non disponibili 2
Totale 9.099
Nazione #
US - Stati Uniti d'America 2.431
SG - Singapore 2.028
CN - Cina 1.026
BR - Brasile 732
HK - Hong Kong 494
VN - Vietnam 478
FR - Francia 255
IT - Italia 209
KR - Corea 183
NL - Olanda 182
BD - Bangladesh 103
AR - Argentina 65
DE - Germania 61
IN - India 61
GB - Regno Unito 54
CA - Canada 47
FI - Finlandia 43
JP - Giappone 42
EC - Ecuador 37
ID - Indonesia 36
MX - Messico 34
ZA - Sudafrica 25
IL - Israele 22
CO - Colombia 21
PL - Polonia 20
ES - Italia 19
PK - Pakistan 17
SA - Arabia Saudita 16
TR - Turchia 16
VE - Venezuela 15
RU - Federazione Russa 14
MA - Marocco 13
PY - Paraguay 13
SE - Svezia 13
IQ - Iraq 12
UA - Ucraina 11
AT - Austria 10
PE - Perù 10
PH - Filippine 10
TN - Tunisia 9
AE - Emirati Arabi Uniti 7
CL - Cile 7
LT - Lituania 7
PA - Panama 7
UZ - Uzbekistan 7
AU - Australia 6
GR - Grecia 6
JM - Giamaica 6
NP - Nepal 6
BG - Bulgaria 5
EG - Egitto 5
KE - Kenya 5
LB - Libano 5
PT - Portogallo 5
BB - Barbados 4
CR - Costa Rica 4
DZ - Algeria 4
GT - Guatemala 4
HN - Honduras 4
IE - Irlanda 4
JO - Giordania 4
PS - Palestinian Territory 4
AZ - Azerbaigian 3
BE - Belgio 3
BY - Bielorussia 3
GE - Georgia 3
HR - Croazia 3
SV - El Salvador 3
TH - Thailandia 3
TT - Trinidad e Tobago 3
AO - Angola 2
BH - Bahrain 2
BO - Bolivia 2
CI - Costa d'Avorio 2
CY - Cipro 2
CZ - Repubblica Ceca 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
ET - Etiopia 2
GA - Gabon 2
HU - Ungheria 2
IS - Islanda 2
KW - Kuwait 2
KZ - Kazakistan 2
LV - Lettonia 2
MD - Moldavia 2
MY - Malesia 2
NZ - Nuova Zelanda 2
OM - Oman 2
RO - Romania 2
RS - Serbia 2
SI - Slovenia 2
SK - Slovacchia (Repubblica Slovacca) 2
TW - Taiwan 2
UY - Uruguay 2
XK - ???statistics.table.value.countryCode.XK??? 2
AF - Afghanistan, Repubblica islamica di 1
AL - Albania 1
AM - Armenia 1
BA - Bosnia-Erzegovina 1
Totale 9.083
Città #
Singapore 1.149
Santa Clara 758
Hong Kong 490
Hefei 380
San Jose 366
Ashburn 217
Beijing 215
Lauterbourg 215
Seoul 179
Ho Chi Minh City 171
Los Angeles 114
Hanoi 107
São Paulo 65
Dallas 49
Buffalo 46
New York 46
Naples 44
Helsinki 40
Frankfurt am Main 31
Da Nang 26
Minamishinagawa 24
Orem 21
Rio de Janeiro 19
Belo Horizonte 16
Bengaluru 16
London 16
Warsaw 16
Chicago 15
Brooklyn 14
Dhaka 14
Houston 14
Tokyo 14
Atlanta 13
Biên Hòa 13
Brasília 13
Haiphong 13
Campinas 12
Guayaquil 12
Stockholm 12
Hải Dương 11
Johannesburg 11
Milan 11
Porto Alegre 11
Quito 11
Seattle 11
Amsterdam 10
Boardman 10
Curitiba 10
Düsseldorf 10
Ninh Bình 10
Phoenix 10
Ribeirão Preto 9
Bắc Giang 8
Denver 8
Falkenstein 8
Paris 8
Portsmouth 8
Asunción 7
Baghdad 7
Chennai 7
Madrid 7
Piscataway 7
Poplar 7
Queens 7
Quận Bình Thạnh 7
Caracas 6
Caxias do Sul 6
Jacksonville 6
Jakarta 6
Lahore 6
Mexico City 6
Miami 6
Milwaukee 6
Phủ Lý 6
Querétaro 6
Quận Phú Nhuận 6
Recife 6
Shanghai 6
Sorocaba 6
Tashkent 6
Boston 5
Buenos Aires 5
Cleveland 5
Franca 5
Hangzhou 5
Jeddah 5
Lima 5
Louisville 5
Manaus 5
Manchester 5
Montes Claros 5
Montreal 5
Mumbai 5
New Delhi 5
Newark 5
Nha Trang 5
Palermo 5
Providence 5
Rome 5
San Francisco 5
Totale 5.416
Nome #
HMGA proteins up-regulate CCNB2 gene in mouse and human pituitary adenomas. 88
Point mutation in GRIM-19: a new genetic lesion in Hurthle cell thyroid carcinomas. 87
Genetic ablation of homeodomain-interacting protein kinase 2 selectively induces apoptosis of cerebellar Purkinje cells during adulthood and generates an ataxic-like phenotype 81
Suppression of transformation by inhibition of HMGI-C protein synthesis: regulatory changes of NF-kB and AP-1 transcription factors. 80
HMGA1: a choice of symmetry 78
HMGA2, but not HMGA1, is overexpressed in human larynx carcinomas 78
A cell proliferation and chromosomal instability signature in anaplastic thyroid carcinoma. 76
POZ-, AT-hook-, and Zinc Finger-containing Protein (PATZ) Interacts with Human Oncogene B Cell Lymphoma 6 (BCL6) and Is Required for Its Negative Autoregulation 76
Altered MicroRNA Expression Profile in Human Pituitary GH Adenomas: Down-Regulation of miRNA Targeting HMGA1, HMGA2, and E2F1 75
The impairment of the High Mobility Group A (HMGA) protein function contributes to the anticancer activity of trabectedin. 75
High mobility group A1 protein expression reduces the sensitivity of colon and thyroid cancer cells to antineoplastic drugs 73
CBX7 gene expression plays a negative role in adipocyte cell growth and differentiation. 73
The b-catenin Axis Integrates Multiple Signals Downstream From RET/PTC and Leads to Cell Proliferation. 71
Characterization of inflammatory infiltrate of ulcerative dermatitis in C57BL/6NCrl-Tg(HMGA1P6)1Pg mice 69
PATZ1 acts as a tumor suppressor in thyroid cancer via targeting p53-dependent genes involved in EMT and cell migration 68
Loss of the CBX7 protein expression correlates with a more aggressive phenotype in pancreatic cancer 67
HIPK2 deficiency causes chromosomal instability by cytokinesis failure and increases tumorigenicity 65
The role of the suppressor genes and of HMGI proteins. 64
A differential proteomic approach to identify proteins associated with thyroid cell transformation 62
HMGA1 silencing reduces stemness and temozolomide resistance in glioblastoma stem cells 59
A ceRNA circuitry involving the long noncoding RNA KLHL14-AS, PAX8, and BCL2 drives thyroid carcinogenesis 59
UbcH10 overexpression may represent a marker of anaplastic thyroid carcinomas. 59
CCDC6 represses CREB1 activity by recruiting histone deacetylase 1 and protein phosphatase 1 58
Setting up and exploitation of a nano/technological platform for the evaluation of HMGA1b protein in peripheral blood of cancer patients. 56
Double knock-out of Hmga1 and Hipk2 genes causes perinatal death associated to respiratory distress and thyroid abnormalities in mice 56
Oncogenic alterations in papillary thyroid cancers of young patients. 56
HMGA1 pseudogenes as candidate proto-oncogenic competitive endogenous RNAs 56
HMGA1-pseudogene overexpression contributes to cancer progression 56
Setting up and exploitation of a nano/technological platform for the evaluation of HMGA1b protein in peripheral blood of cancer patients. Nanomedicine. 55
Impairment of the p27kip1 function enhances thyroid carcinogenesis in TRK-T1 transgenic mice 55
Isolation and functional characterization of peptide agonists of PTPRJ, a tyrosine phosphatase receptor endowed with tumor suppressor activity. 54
Identification and Synthesis of Mycalol Analogues with Improved Potency against Anaplastic Thyroid Carcinoma Cell Lines. 54
HIPK2 controls cytokinesis and prevents tetraploidization by phosphorylating histone H2B at the midbody. 54
In ataxia-teleangiectasia betamethasone response is inversely correlated to cerebellar atrophy and directly to antioxidative capacity. 53
The High Mobility Group A proteins contribute to thyroid cell transformation by regulating miR-603 and miR-10b expression. 53
High-mobility group A1 protein: a new coregulator of peroxisome proliferator-activated receptor-?-mediated transrepression in the vasculature. 53
The metallophosphoesterase-domain-containing protein 2 (MPPED2) gene acts as tumor suppressor in breast cancer 53
HMGA2 cooperates with either p27 deficiency or Cdk4 mutation in pituitary tumorigenesis. 52
AP-1 compositional changes in transformed thyroid cells: role of fra-1 induction and functional interaction with the HMGI-C gene product. 51
miR-155 is positively regulated by CBX7 in mouse embryonic fibroblasts and colon carcinomas, and targets the KRAS oncogene 51
Oncogenic Properties of the Antisense lncRNA COMET in BRAF- and RET-Driven Papillary Thyroid Carcinomas 51
Reduced E-cadherin expression contributes to the loss of p27kip1-mediated mechanism of contact inhibition in thyroid anaplastic carcinomas. 50
Characterization of HMGA1P6 transgenic mouse embryonic fibroblasts 50
The receptor-type protein tyrosine phosphatase J antagonizes the biochemical and biological effects of RET-derived oncoproteins. 50
Tumour Suppressor Role of the CL2/DRO1/CCDC80 Gene in Thyroid Carcinogenesis. 50
MPPED2 is downregulated in glioblastoma, and its restoration inhibits proliferation and increases the sensitivity to temozolomide of glioblastoma cells 50
PATZ1 interacts with p53 and regulates expression of p53-target genes enhancing apoptosis or cell survival based on the cellular context 49
Identification of HMGA2 inhibitors by AlphaScreen-based ultra-high-throughput screening assays 49
HMGA and cancer: A review on patent literatures 49
UbcH10 expression can predict prognosis and sensitivity to the antineoplastic treatment for colorectal cancer patients 49
Pax8 has a critical role in epithelial cell differentiaion, survival and proliferation. 49
Hmga1/Hmga2 double knock-out mice display a "superpygmy" phenotype 48
The lncRNA RMST is drastically downregulated in anaplastic thyroid carcinomas where exerts a tumor suppressor activity impairing epithelial-mesenchymal transition and stemness 48
Deregulation of HMGA1 expression induces chromosome instability through regulation of spindle assembly checkpoint genes 48
The cl2/dro1/ccdc80 null mice develop thyroid and ovarian neoplasias 48
PATZ1 is a target of miR-29b that is induced by Ha-Ras oncogene in rat thyroid cells 48
Restoration of CBX7 expression increases the susceptibility of human lung carcinoma cells to irinotecan treatment 48
Critical role of the high mobility group A proteins in hematological malignancies 47
Drug-induced inhibition of HMGA and EZH2 activity as a possible therapy for anaplastic thyroid carcinoma 47
Loss of CCDC6, the first identified RET partner gene, affects pH2AX S139 levels and accelerates mitotic entry upon DNA damage. 47
Regulation of microRNA expression by HMGA1 proteins. 46
Histone deacetylase inhibitors induce thyroid cancer-specific apoptosis through proteasome-dependent inhibition of TRAIL degradation. 46
The HMGA1-pseudogene7 shows oncogenic activity in vivo 46
Molecular characterization of RET/PTC3; a novel rearranged version of the RET proto-oncogene in a human thyroid papillary carcinoma 46
Transgenic mice overexpressing the wild-type form of the HMGA1 gene develop mixed growth hormone/prolactin cell pituitary adenomas and natural killer cell lymphomas. 46
Critical role of HMGA proteins in cancer cell chemoresistance 46
The highly malignant phenotype of anaplastic thyroid carcinoma cell lines is recessive. 45
Complex regulation of the cyclin-dependent kinase inhibitor p27kip1 in thyroid cancer cells by the PI3K/AKT pathway: regulation of p27kip1 expression and localization. 45
CBX7 is a tumor suppressor in mice and humans 45
The rat tyrosine phosphatase eta increases cell adhesion by activating c-Src through dephosphorylation of its inhibitory phosphotyrosine residue. 45
Role of Dicer1 in thyroid cell proliferation and differentiation 45
Regulation of p27Kip1 protein levels contributes to mitogenic effects of the RET/PTC kinase in thyroid carcinoma cells. 45
Deregulation of microRNA expression in thyroid neoplasias 44
MIR191 (microRNA 191) 44
Hmga1null mouse embryonic fibroblasts display downregulation of spindle assembly checkpoint gene expression associated to nuclear and karyotypic abnormalities 44
The long non-coding RNA RP5-1024C24.1 and its associated-gene MPPED2 are down-regulated in human thyroid neoplasias and act as tumour suppressors 44
Histone deacetylase inhibitors induce thyroid cancer-specific apoptosis through proteasome-dependent inhibition of TRAIL degradation. 44
MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle 44
HMGA2 overexpression plays a critical role in the progression of esophageal squamous carcinoma 44
HMGA1-pseudogene expression is induced in human pituitary tumors 43
miR-130b-3p Upregulation Contributes to the Development of Thyroid Adenomas Targeting CCDC6 Gene. 43
The HMGA1 Pseudogene 7 Induces miR-483 and miR-675 Upregulation by Activating Egr1 through a ceRNA Mechanism 43
miR-142-3p Down-Regulation Contributes to Thyroid Follicular Tumorigenesis by Targeting ASH1L and MLL1 42
Chromobox protein homologue 7 protein, with decreased expression in human carcinomas, positively regulates E-cadherin expression by interacting with the histone deacetylase 2 protein. 42
RET/papillary thyroid cancer rearrangement in nonneoplastic thyrocytes: follicular cells of Hashimoto's thyroiditis share low-level recombination events with a subset of papillary carcinoma 42
Enhancer of zeste homolog 2 overexpression has a role in the development of anaplastic thyroid carcinomas. 42
TWIST1 plays a pleiotropic role in determining the anaplastic thyroid cancer phenotype. 42
HMGA1-pseudogene7 transgenic mice develop B cell lymphomas 42
HMGA1 Expression in Human Hepatocellular Carcinoma Correlates with Poor Prognosis and Promotes Tumor Growth and Migration in in vitro Models. 42
Critical role of CCDC6 in the neoplastic growth of testicular germ cell tumors. 42
CBX7 Modulates the Expression of Genes Critical for Cancer Progression 42
Therapy of human pancreatic carcinoma based on suppression of HMGA1 protein synthesis in preclinical models. 42
HMGA2 cooperates with either p27kip1 deficiency or Cdk4R24C mutation in pituitary tumorigenesis Cell Cycle 42
PATZ attenuates the RNF4-mediated enhancement of androgen receptor-dependent transcription. 41
UBE2C is a transcriptional target of the cell cycle regulator FOXM1 41
Analysis of UbcH10 expression represents a useful tool for the diagnosis and therapy of astrocytic tumors. 41
HMGA proteins promote ATM expression and enhance cancer cell resistance to genotoxic agents 41
HMGA1 negatively regulates NUMB expression at transcriptional and post transcriptional level in glioblastoma stem cells 41
Epigenetic Mechanisms Leading to Overexpression of HMGA Proteins in Human Pituitary Adenomas. 41
Structural Model of the hUbA1-UbcH10 Quaternary Complex: In Silico and Experimental Analysis of the Protein-Protein Interactions between E1, E2 and Ubiquitin. 41
Totale 5.266
Categoria #
all - tutte 31.544
article - articoli 28.745
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 313
Totale 60.602


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/202462 0 0 0 0 0 0 0 0 13 1 40 8
2024/20253.413 18 15 309 136 673 122 89 162 132 246 813 698
2025/20265.515 255 515 546 894 1.105 206 716 259 265 249 213 292
2026/2027174 174 0 0 0 0 0 0 0 0 0 0 0
Totale 9.164